Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion.

The article presents a study which aims to determine whether ublituximab could be considered an adapted treatment for the group of high-risk chronic lymphocytic leukemia (CLL) patients. It notes that antibody-dependent cellular cytotoxicity (ADCC) efficacy is more dependent on the intrinsic resistance of the CLL target cells than on the natural killer (NK) cell functionality. It concludes that ublituximab showed a promising overall response rate in CLL patients at a relatively low-dose regimen.